GDF15 antibody (C-Term) (HRP)

Catalog No. ABIN1043915

Supplier Product No.: 600-403-b07

The Rabbit Polyclonal anti-GDF15 antibody has been validated for WB, ELISA and IHC. It is suitable to detect GDF15 in samples from Human and Mouse. There is 1 publication available.

Quick Overview for GDF15 antibody (C-Term) (HRP) (ABIN1043915)

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This GDF15 antibody is conjugated to HRP

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Product Details anti-GDF15 Antibody (HRP)

Binding Specificity: C-Term

Supplier Product No.: 600-403-b07

Supplier: Rockland

Purpose: GDF15 Antibody Peroxidase Conjugated

Cross-Reactivity (Details): This antibody reacts with the C-terminus of endogenous NAG-1 protein from human and mouse tissues.

Characteristics: Synonyms: rabbit anti-NAG1 antibody peroxidase conjugation, HRP conjugated rabbit anti-NAG1 antibody, NAG 1, NAG-1, GDF15, MIC1, MIC-1, GDF-15, PLAB, PTGFB, nonsteroidal anti-inflammatory drug-activated gene, NSAID-activated gene 1 protein, growth differentiation factor 15, macrophage inhibitory compound 1, Placental bone morphogenetic protein, Prostate differentiation factor

Purification: Anti-NAG-1 (C-terminal specific) was affinity purified from monospecific antiserum by immunoaffinity chromatography.

Immunogen:

Immunogen: Anti-NAG-1 (C-terminal specific) antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the carboxy terminal end of human NAG-1 protein.  A residue of cysteine was added to facilitate coupling to KLH.

Immunogen Type: Conjugated Peptide

Isotype: IgG

Application Details

Application Notes:

Immunohistochemistry Dilution: 1:500-1:2,500

Application Note: Anti-NAG1/GDF15 (C-terminal specific) antibody has been tested by ELISA and is suitable for IHC and western blotting of human and mouse NAG-1 protein.  For detection of NAG-1 in human serum, a sandwich ELISA is suggested using this antibody in combination with anti-NAG-1/GDF15 (N-terminal), H variant or D variant specific antibodies.  Specific conditions for reactivity should be optimized by the end user.  Expect bands in Western blots of approximately 14 and 28 kDa in size corresponding to NAG-1 monomer and dimer, respectively, using the appropriate cell lysate or extract.

Western Blot Dilution: 1:1,000-1:5,000

ELISA Dilution: 1:10,000-1:50,000

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution:

Reconstitution Volume: 100 μL

Reconstitution Buffer: Restore with deionized water (or equivalent)

Concentration: 1.07 mg/ml

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Stabilizer: 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free

Preservative: 0.01 % (w/v) Gentamicin Sulfate. Do NOT add Sodium Azide!

Preservative: Gentamicin sulfate

Precaution of Use: This product contains Gentamicin sulfate: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store vial at 4° C prior to restoration.   For extended storage aliquot contents and freeze at -20° C or below.  Avoid cycles of freezing and thawing.  Centrifuge product if not completely clear after standing at room temperature.  This product is stable for several weeks at 4° C as an undiluted liquid.  Dilute only prior to immediate use. 

Expiry Date: 12 months

References for anti-GDF15 antibody (HRP) (ABIN1043915)

Baek, Eling: "Changes in gene expression contribute to cancer prevention by COX inhibitors." in: Progress in lipid research, Vol. 45, Issue 1, pp. 1-16, (2006) (PubMed).

Target Details for GDF15

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Alternative Name: GDF15

Background: Background: Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.

Gene ID: 9518

UniProt: Q99988

Pathways: SARS-CoV-2 Protein Interactome